Ross Moat

Ross Moat

Executive Vice President and Chief Commercial OfficeratKiniksa Pharmaceuticals International· In proxies 2022–2025

Pay in FY2025+56% from the year before · Kiniksa Pharmaceuticals International stock +108.5% the same year

Ross Moat was paid $3.6M in FY2025 (Dec), up 56%. Kiniksa Pharmaceuticals International stock rose 108.5% that year.

Pay$100 in the stock at the end of FY21 → $350
Pay is from the Summary Compensation Table of each Kiniksa Pharmaceuticals International proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kiniksa Pharmaceuticals InternationalPublic company · 4 yr
    • Executive Vice President and Chief Commercial Officer2022 – Present · 4 yrStock in role +662%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?